I've wondered similar things greedy, but the one thing that keeps snapping me back to this being sooo undervalued is that it's at that point in a company's life cylce that the momentum has begun.
Patersons et al are there to make money and they don't do that unless they churn stock, preferably at a higher price than what they bought it at if they're going long. They don't get too attached to stocks, just the casheesh.
All I know is that once deals start materializing in biotech stocks then they rock and roll pretty quickly thereafter. The last couple of years have been the nose to the grindstone, get the technology developed and keep the head above water.
If we're now getting to the reward end of the cycle, then there'll be a big step change on the way this share is treated.
There's no certainties, but it's all about maximizing upside potential and minimizing downside risk. At this point I'll be surprised if we don't get a major rerate in the next 6 months.
Fingers crossed and lets see where she goes from here.
PYC Price at posting:
7.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)